மானியம் லார்சன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aequus sees fiscal 2020 revenue rise by 59%, driven by strong sales of Vistitan and Tacrolimus For the year ended December 31, 2020, it reported revenue of $2.6 million, compared to $1.6 million during the year ended December 31, 2019 COO Grant Larsen said that Vistitan revenue at +15% and Tacrolimus at +49% showed strong consistent growth Aequus Pharmaceuticals Inc. (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) posted fiscal 2020 results that saw its annual revenue jump 59% year-over-year on the back of strong sales led by PRVistitan and Tacrolimus eye treatments.      For the year ended December 31, 2020, the Vancouver, British Columbia-based specialty pharmaceutical company reported its highest annual revenue to date of $2.6 million, up 59%, compared to $1.6 million during the year ended December 31, 2019. The company chalked the bump in revenue to higher sales. 

United kingdomBritish columbiaDoug janzenPrvistitan bimatoprostHealth canadaBritish columbia basedChairman doug janzenGrant larsenஒன்றுபட்டது கிஂக்டம்பிரிட்டிஷ் கொலம்பியாடக் ஜான்சன்ஆரோக்கியம் கனடாபிரிட்டிஷ் கொலம்பியா அடிப்படையிலானதுமானியம் லார்சன்